Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in Pennsylvania
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Pennsylvania
| Provider | Medicare | Services |
|---|---|---|
| Quest Diagnostics Of Pennsylvania,... | $171.52 | 20 |
Pennsylvania Pricing in Context
In Pennsylvania, CPT code 0014M (Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test)) carries an average Medicare payment of $171.82 — 0% below the national benchmark of $172.16. 4 providers across the state submitted claims for this procedure in 2023, performing 27 total services. Individual payments in PA ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Pennsylvania is $421.78, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Pennsylvania sits below the national Medicare average, commercial rates in the state may also run lower than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Other procedures, the estimated commercial insurance price in Pennsylvania lands near $378.00, with self-pay cash prices typically around $244.85. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cost in Pennsylvania?
The average Medicare payment for Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in Pennsylvania is $171.82, which is 0% below the national average of $172.16. Providers in PA typically bill $421.78 for this procedure.
What does Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cost with insurance in Pennsylvania?
With commercial insurance in Pennsylvania, Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) costs an estimated $378.00. Without insurance, the estimated cash price is $244.85. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in Pennsylvania?
4 providers in Pennsylvania billed Medicare for Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) in 2023, performing 27 total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) cheaper in Pennsylvania than the national average?
Yes — Molecular Pathology Test For Risk Of Serious Liver Disease Within 5 Years (enhanced Liver Fibrosis (elf) Test) costs 0% below the national average in Pennsylvania. The state average Medicare payment is $171.82 compared to $172.16 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.